WA company Epichem and the Drugs for Neglected Diseases initiative are collaborating to develop new drugs to treat African sleeping sickness and similar, forgotten diseases.

Nature reports that a peer reviewer leaked an unfavourable report on diabetes drug Avandia to manufacturer.

The annual Research Australia Thank You Day awards have been announced.

Two new vaccines against rotavirus infection have been added to the PBS.

GSK to launch up to five major cancer drugs in next three years.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.

GlaxoSmithKline says early trials show its split antigen avian flu vaccine is effective against other strains.

Just as the HPV vaccine Gardasil receives FDA approval, an argument has broken out between the researchers involved in the vaccine's development. So who patented what?

A leading researcher has raised the ire of CSL (ASX:CSL), saying the Melbourne company is "making the wrong vaccine for bird flu."

To no one's surprise, CSL has become the dominant force in the Australian biotechnology sector. Graeme O'Neill learns from CSL's chief scientist, Andrew Cuthbertson, about the solid research that will drive the company in the next few years.

Clinical trials have found that GlaxoSmithKline's anti-blood clotting drug Arixtra nearly halved the risk of blood clots in acutely ill patients, a result that is expected to boost the commercial prospects of Brisbane-based Alchemia's (ASX:ACL) generic version of the drug.